The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Carmustine. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carmustine. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carmustine. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carmustine. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Carmustine. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carmustine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carmustine. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carmustine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Carmustine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Carmustine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carmustine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Carmustine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Carmustine. |
| Cladribine | Carmustine may increase the immunosuppressive activities of Cladribine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Carmustine is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Carmustine is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Carmustine is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Carmustine is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Carmustine is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Carmustine is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Carmustine is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Carmustine is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Carmustine is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Carmustine is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Carmustine is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Carmustine is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Carmustine is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Carmustine is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Carmustine is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Carmustine is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Carmustine is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Carmustine is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Carmustine is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Carmustine is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Carmustine is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Carmustine is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Carmustine is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Carmustine is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Carmustine is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Carmustine is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Carmustine is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Carmustine is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Carmustine is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Carmustine is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carmustine is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Carmustine is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Carmustine is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Carmustine is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Carmustine is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Carmustine is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Carmustine is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Carmustine is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Carmustine is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Tretinoin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Carmustine is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Carmustine is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Carmustine is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Carmustine is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Carmustine is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Carmustine is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Carmustine is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Carmustine is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Carmustine is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carmustine is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Carmustine is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Carmustine is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Carmustine is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Carmustine is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Carmustine is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Carmustine is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Carmustine is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Carmustine is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Carmustine is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Carmustine is combined with Thalidomide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Carmustine is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Carmustine is combined with Capecitabine. |
| Trilostane | The risk or severity of adverse effects can be increased when Carmustine is combined with Trilostane. |
| Procarbazine | The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine. |